We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.
- Authors
Ubals, Maria; Bosch-Nicolau, Pau; Sánchez-Montalvá, Adrián; Salvador, Fernando; Aparicio-Español, Gloria; Sulleiro, Elena; Silgado, Aroa; Soriano-Arandes, Antoni; Espiau, Maria; Ferrer, Berta; Pou, Diana; Treviño, Begoña; Molina, Israel; García-Patos, Vicente
- Abstract
Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
- Subjects
AMPHOTERICIN B; CUTANEOUS leishmaniasis; TREATMENT failure; MEDICAL personnel; LEISHMANIASIS; MEDICATION safety; DRUG utilization; MUCORMYCOSIS
- Publication
Pathogens, 2021, Vol 10, Issue 10, p1253
- ISSN
2076-0817
- Publication type
Article
- DOI
10.3390/pathogens10101253